Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.
Press releases published on May 24, 2025
Bridging the Gap in Schizophrenia Care: A Call for Comprehensive Rehabilitation in India
EIN Presswire
·
May 24, 2025
MindPlus, a regional pioneer in holistic mental health care, organized session today at MindPlus Doraha to mark World Schizophrenia Day. LUDHIANA, PUNJAB, INDIA, May 24, 2025 /EINPresswire.com/ -- On the occasion of World Schizophrenia Day, observed …
SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN
GlobeNewswire
·
May 24, 2025
– im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN – – die Entscheidung der Europäischen Kommission wird für das dritte Quartal 2025 erwartet – STAMFORD, Conn., …
SpringWorks Therapeutics reçoit un avis favorable du CMUH pour l’utilisation du mirdamétinib pour le traitement des patients adultes et pédiatriques atteints de NF1-PN
GlobeNewswire
·
May 24, 2025
– S’il est approuvé, le mirdamétinib devrait être le premier et unique traitement dans l’Union européenne à bénéficier d’une autorisation de mise sur le marché pour les adultes et les enfants atteints de NF1-PN – – La décision de la Commission européenne …
SpringWorks Therapeutics: CHMP valuta positivamente Mirdametinib per il trattamento di pazienti adulti e pediatrici affetti da NF1-PN
GlobeNewswire
·
May 24, 2025
– Se approvato, mirdametinib sarà la prima e unica terapia nell'Unione europea a ottenere l'autorizzazione all'immissione in commercio sia per gli adulti che per i bambini affetti da NF1-PN – – La decisione della Commissione europea è prevista nel terzo …
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
GlobeNewswire
·
May 24, 2025
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily …